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Abstract: Rasagiline (N-propargyl-1 (R)-aminoindan) is a novel propargylamine, irreversible, 
selective monoamine oxidase inhibitor for treatment of Parkinson’s disease (PD), a progressive 
condition associated with degeneration of dopaminergic neurons in the substantia nigra. Rasa-
giline inhibits striatal dopamine metabolism, thereby providing relief from motor symptoms 
of PD. It may be dosed once daily and, unlike selegiline, it is metabolized to non-amphetamine 
compounds. In a large clinical trial, rasagiline has proved effective, safe, and well tolerated in 
early PD as monotherapy. In two phase III clinical trials in advanced PD with motor ﬂ  uctuations, 
rasagiline as an adjunct to levodopa signiﬁ  cantly decreases “off” time. In animal models of 
PD, data supports a neuroprotective effect of rasagiline, and its active metabolite aminoindan. 
Analysis of delayed-start clinical trial suggests the potential for disease modiﬁ  cation, and further 
trials are examining this effect.
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Introduction
Parkinson’s disease (PD) is a progressive, incurable, neurodegenerative disorder 
characterized by cardinal motor features of bradykinesia, rigidity, and rest tremor 
(in the majority), with postural instability occurring later in the disease (Fahn 2003). 
Most of the motor disability experienced by patients results from progressive loss of 
dopaminergic neurons of the substantia nigra pars compacta (SNpc). These neurons 
project to the medium spiny neurons of the striatum, where dopamine is released 
onto dopamine D1 and D2 receptor subtypes, resulting in modulation of complex 
downstream pathways. However, recent advances have emphasized that PD is a mul-
tisystem disorder which affects not only the dopaminergic neurons in the SNpc but 
also other neurotransmitter systems, including noradrenergic, cholinergic and sero-
tonergic systems (Lang and Obeso 2004). Braak proposed a staging system based on 
alpha-synuclein pathology, suggesting that early changes are seen in the dorsal motor 
nucleus of vagus and the anterior olfactory structures, and that the SNpc is involved 
only later in the disease (Braak et al 2003), emphasizing the need for earlier disease 
detection and neuroprotective interventions.
Recent strides have changed the face of PD treatment. Among these are the 
development of new therapeutic agents, including selective monoamine oxidase 
inhibitors (MAOI). Monoamine oxidase (MAO), an integral enzyme of the outer 
mitochondrial membrane, is present in peripheral organs and neuronal cells. Of 
the two isoforms, MAO-A is found predominantly in non-neuronal tissue, while 
MAO-B is the major isoform in the brain. MAO-B is abundant in the striatum, 
and is involved in dopamine metabolism (Figure 1) (Collins et al 1970; Squires 
1972; O’Carroll et al 1983; Riederer and Youdim 1986; Green et al 1977). Selec-
tive MAOIs are therefore of great interest to improve PD motor symptoms by 
augmenting striatal dopamine (Riederer et al 2004; Youdim and Riederer 2004). 
Until recently, selegiline was the only selective MAO-B inhibitor indicated for 
PD treatment. The landmark DATATOP trial demonstrated efﬁ  cacy and safety in Neuropsychiatric Disease and Treatment 2008:4(1) 24
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Figure 1 Dopamine metabolism and rasagiline:In the brain, MAO-B catalyzes dopamine metabolism to DOPAC (3, 4-dihydroxyphenylacetic acid) and breakdown of the 
dopamine metabolite, 3-methoxytyramine into 3-methoxy-4-hydroxy-phenylacetic acid. Rasagiline results in irreversible inhibition of MAO-B.
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demonstrated across multiple species in platelets, brain and 
liver, therefore duration of effect likely depends on rate of 
MAO-B synthesis (Youdim et al 2001; Youdim and Tipton 
2002). Positron emission tomography (PET) scans using an 
L-[11C] Deprenyl tracer, demonstrated 80% recovery of 
tracer binding by 4–6 weeks after the last rasagiline dose in 
3 healthy volunteers taking rasagiline 1 mg daily for a 10-day 
period, consistent with the previously reported half life for 
MAO-B synthesis of approximately 40 days (Fowler et al 
1994; Freedman et al 2005).
Rasagiline is almost completely eliminated by oxida-
tive metabolism (catalyzed by cytochrome P450 isoenzyme 
1A2) followed by renal excretion of the parent conjugated 
compound and its metabolites (Chen and Swope 2005). Its 
major metabolite is 1-(R)-aminoindan (Figure 2), a non-
amphetamine compound, thus avoiding potential deleteri-
ous activity associated with the amphetamine metabolite of 
selegiline (Rabey et al 2000). This active metabolite likely 
contributes to the effects of rasagiline: 1-(R)-aminoindan 
administered at a dose of 0.5 mg/kg/day over 80 days in brain 
homogenates of hypoxic rats led to 43% MAO-B activity 
inhibition and 6% MAO-A activity inhibition (Speiser et al 
1998). Like rasagiline, Cmax and AUC for 1-(R)-aminoindan is 
early PD (1989, 1993). However, there has been concern 
over potential deleterious effects of its amphetamine and 
methamphetamine metabolites that remain to be resolved. 
Rasagiline (AzilectTM: Teva; AgilectTM: Teva-Eisai) is a 
new MAO-B inhibitor (Finberg et al 1996; Youdim et al 
2001) that is indicated for use in treatment of early and 
advanced PD. Unlike selegiline, it has no methamphet-
amine and amphetamine metabolites. Its potential for a 
neuroprotective effect is currently under clinical investiga-
tion, and is discussed in this paper.
Rasagiline
Rasagiline (Figure 2, TVP-1012, N-propargyl-1(R)-
aminoindan) is a novel, potent, irreversible, and highly 
selective MAO-B inhibitor, that provides a new option 
in treatment of early and advanced PD. Rasagiline most 
likely exerts its primary effect in PD by MAO-B inhibi-
tion, resulting in slower metabolism of endogenous and 
exogenous dopamine, thus providing symptomatic beneﬁ  t 
(Finberg et al 1996, 1998). However, there is now increasing 
evidence for an anti-apoptotic effect, unrelated to MAO-B 
inhibition (Finberg et al 1998; Youdim et al 2001; Mandel 
et al 2005).
Pharmacokinetics, pharmacodynamics, 
and metabolism
A randomized, double-blind, placebo-controlled single-dose 
and repeated-dose study was undertaken in 36 healthy male 
volunteers (18–40 years old) investigating rasagiline doses 
up to 20 mg daily. Single doses resulted in signiﬁ  cant inhi-
bition of platelet MAO-B activity, and repeat doses led to 
almost full inhibition of platelet MAO-B activity (Thebault 
et al 2004). In 56 PD patients, a randomized, double-blind, 
placebo-controlled, 10-week study of 1 mg, 2 mg, or 4 mg 
rasagiline daily, revealed a half-life of 1.34 hours, volume of 
distribution of 182 L, clearance of 94.3 L/hour, and median 
time to Cmax of 0.5 hours (dose-independent) (Stern et al 
2004). The mean area under the curve (AUC) and mean 
peak plasma concentration were linearly proportional to 
rasagiline dose. In rat brain tissue ex vivo, a single rasagi-
line dose inhibited MAO-B at 0.1 ± 0.01 mg/kg, compared 
with 6.48 ± 0.81 mg/kg for MAO-A inhibition. Rasagiline 
was 3–15 times more potent than selegiline for inhibition of 
MAO-B in rat brain and liver in vivo on acute and chronic 
administration (Youdim et al 2001).
The mechanism of rasagiline action allows once 
daily dosing. Irreversible MAO-B inhibition has been 
Figure 2 Chemical formulae of the selective irreversible MAO-B inhibitors rasagi-
line, and aminoindan, its major metabolite.
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dose-dependent (Cmax: 1.6 ng/mL, 2.6 ng/mL, and 7.1 ng/mL; 
AUC: 4.6 ng·h/ mL, 10.1 ng·h/ mL, and 21.0 ng·h/ mL for 
0.5 mg, 1 mg, and 2 mg daily doses respectively).
Clinical studies
Monotherapy in early PD
A pilot double-blind, randomized, placebo-controlled, 
parallel-group, dose-ranging study in 56 unmedicated 
subjects with early PD was conducted at 9 centers in the 
USA. The primary objective was evaluation of safety and 
tolerability of rasagiline as monotherapy at doses of 1 mg, 
2 mg, and 4 mg daily, over a 10-week period (Stern et al 
2004). A 3-week dose-escalation was followed by 7 weeks 
of dose-maintenance. Although this study was not powered 
to test efﬁ  cacy, post-hoc repeat measure analysis revealed 
signiﬁ  cant improvement in total Uniﬁ  ed Parkinson’s Disease 
Rating Scale (UPDRS) score in the rasagiline arm, compared 
with placebo (placebo: −0.5 ± 0.8; 1 mg: −1.8 ± 1.3; 2 mg: 
−3.6 ± 1.7; 4 mg: −3.6 ± 1.2). The percentage of responders, 
as deﬁ  ned by  30% improvement in UPDRS score, was 
28% in all arms taking rasagiline compared with 0% in the 
placebo group (p   0.05).
TVP-1012 in early monotherapy 
for Parkinson’s disease outpatients (TEMPO) 
(Parkinson Study Group 2002)
The TEMPO trial was a randomized, multicenter, placebo 
controlled, double-blind, phase 3 clinical trial conducted 
over 6 months to determine the efﬁ  cacy, safety, and toler-
ability of rasagiline in untreated patients with early PD. This 
trial enrolled 404 subjects at 32 sites in the United States 
and Canada. Eligibility criteria included age  35, with at 
least 2 cardinal signs of PD, and disease severity less than 
Hoehn and Yahr stage III. Clinically signiﬁ  cant depression, 
Mini-Mental State Examination (MMSE) score of 23 or less, 
or psychiatric disease that might impact upon the informed 
consent process were grounds for exclusion. Amitriptyline, 
paroxetine, sertraline, ﬂ  uvoxamine, and trazodone were the 
only antidepressants allowed. Patients were randomly assigned 
to one of 3 groups: rasagiline 1 mg/day, rasagiline 2 mg/day, 
and placebo. Primary outcome was change in UPDRS score 
between baseline and week 26. Those who experienced a 
worsening of less than 3 units in their total UPDRS score were 
classiﬁ  ed as responders. The primary statistical analyses were 
performed based on an intention-to-treat principle.
Subjects were well matched, with mean age of 60–61 
years, mean disease duration of 0.92–1.15 years, and Schwab 
and England activities of daily living (ADL) scores of 
approximately 90%. There were no signiﬁ  cant differences 
among groups with regard to total UPDRS or motor subscale 
scores at baseline. Both rasagiline groups had signiﬁ  cantly 
greater improvement in mean total UPDRS scores (1 mg 
group: 4.2 points more than placebo; 2 mg group: 3.5 points 
more than placebo, p   0.001). There were 49%, 66%, and 
67% responders in the placebo, 1 mg, and 2 mg groups 
respectively. Kaplan-Meier analysis showed no statisti-
cally signiﬁ  cant difference in the time needed for additional 
therapy with levodopa among the 3 groups. Of the subjects 
taking placebo, 1 mg rasagiline and 2 mg rasagiline, 16.7%, 
11.2%, and 16.7% respectively, required levodopa. A num-
ber of secondary endpoints were investigated, including a 
quality of life scale (PDQUALIF), which of note suggested 
improvement in both the 1 mg and 2 mg rasagiline groups, 
compared with placebo (mean effect size for 1 mg: −2.91, 
95% [conﬁ  dence interval] CI −5.19 to −0.64; mean effect 
size for 2 mg: −2.74, 95% CI −5.02 to −0.45).
Infection and headache were the most commonly 
reported adverse events, and occurred at similar rates in 
rasagiline and placebo groups. There was no signiﬁ  cant 
difference between groups in early termination, and com-
pliance was excellent (92% of those taking 1 mg rasagiline 
and 89.4% of those taking 2 mg rasagiline daily had  95% 
compliance). In the rasagiline 2 mg arm, one subject 
developed malignant melanoma, and one was hospitalized 
for depression and developed delirium. There was a small 
but signiﬁ  cant increase in supine blood pressure in the 2 
mg group (4 mmHg, p = 0.02), but no differences in EKG, 
pulse, or standing blood pressure.
Controlled, randomized, delayed-start study of 
rasagiline in early PD (Parkinson Study Group 2004)
On the basis of preclinical studies which suggested that rasa-
giline may modify the progression of PD, the aforementioned 
TEMPO study was extended to a total period of 1 year. The 
objective of this trial was comparison of the effects of early 
and delayed initiation of rasagiline on progression of dis-
ability in patients with PD; in short, to look for evidence of a 
disease-modifying or neuroprotective effect. At the 6-month 
endpoint of the TEMPO trial, patients taking 1 mg or 2 mg 
rasagiline daily continued at the same doses, whereas those 
taking placebo were now assigned to take rasagiline 2 mg. 
The underlying rationale was that at the end of 1 year, all 
subjects would be taking rasagiline and symptomatic beneﬁ  ts 
would be comparable, therefore any difference would sug-
gest modiﬁ  cation of disease progression, unaccounted for by 
short term effects alone.Neuropsychiatric Disease and Treatment 2008:4(1) 27
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Of 404 TEMPO study subjects, 371 entered the second 
part of the study (46 entered the active phase early at the 
discretion of the investigators: there was no difference 
between groups), and 259 patients completed the study on 
the assigned doses of rasagiline alone, without the need for 
additional dopaminergic therapy as judged by the investiga-
tors. At the end of 52 weeks, the change in mean total UPDRS 
from baseline was −3.01 ± 8.26 for those assigned to 1 mg 
rasagiline, −1.97 ± 7.49 for the 2 mg group, and −4.17 ± 8.83 
for the delayed 2 mg group. There was a signiﬁ  cant advantage 
seen in those taking rasagiline 1 mg for 1 year over those 
taking 2 mg for 6 months (mean total UPDRS difference 
−1.82 units; 95% CI –3.64 to 0.01 units; p = 0.05), as well 
as in those taking 2 mg for 1 year over 2 mg for 6 months 
(mean total UPDRS difference −2.29 units; 95% CI −4.11 
to –0.48 units; p = 0.01).
There was a higher percentage of responders in the 
2 mg/day rasagiline for 1 year group (63.8%), compared to 
52.5% in the 1 mg/day for 1 year, and 52.3% in the 2 mg/
day for 6 months group. As secondary outcome measures, 
ADL scores were signiﬁ  cantly higher in the 2 mg/day for 
1 year group, as compared to the delayed rasagiline group 
(p   0.005). There was no difference in other subscales and 
no difference in time to initiation of additional dopaminergic 
therapy. This delayed treatment trial suggests that rasagiline 
has a disease-modifying effect, and this is certainly supported 
by its effects on cell physiology in vitro and on dopaminergic 
neurons in animal models (see below). A further trial, A 
Multi Center, Double Blind, Randomized Start, Placebo-
Controlled, Parallel-Group Study to Assess Rasagiline 
as a Disease Modifying Therapy in Early Parkinson’s 
Disease Subjects (ADAGIO, see www.clinicaltrials.gov, 
NCT00256204) has now completed enrollment and aims to 
extend and conﬁ  rm these observations.
Adjunctive therapy to levodopa in PD
In patients with advanced PD on levodopa, motor ﬂ  uc-
tuations and dyskinesias result in signiﬁ  cant morbidity and 
disability. The following two large phase 3 trials were con-
ducted to determine the beneﬁ  t of rasagiline in this subset 
of patients.
Parkinson’s rasagiline: efﬁ  cacy and safety in the 
treatment of “Off” (PRESTO) trial (Parkinson Study 
Group 2005)
The PRESTO trial is a 26-week, multicenter, randomized, 
double-blind, placebo-controlled study of parallel groups of 
subjects with PD on optimized levodopa therapy, with motor 
ﬂ  uctuations. Efﬁ  cacy, safety, and tolerability of rasagiline as 
a levodopa adjunct were evaluated in 472 subjects enrolled 
at 57 centers. Inclusion criteria were idiopathic PD with 
modiﬁ  ed Hoehn and Yahr stage  5 in the “off” state, and 
presence of  2.5 hours of “off” time daily. Those with 
atypical or secondary parkinsonism, pronounced cognitive 
impairment (MMSE 23 or less), depression (judged by Beck 
Depression Inventory score of 16 or greater), and unstable 
neurological and medical disorders were excluded. There 
was no tyramine restriction required for subjects’ diets. 
Subjects were on optimized, stable doses of levodopa for at 
least 2 weeks prior to starting the study, and could receive 
concomitant treatment with dopamine agonists, amantadine, 
anticholinergics, and catechol-O-methyltransferase (COMT) 
inhibitors. The levodopa dose could be decreased in the ﬁ  rst 
6 weeks, but not thereafter.
Subjects were randomized to 0.5 mg/day or 1 mg/day 
rasagiline, or placebo. The primary outcome measure was 
change from baseline in mean total “off” time, determined 
on the basis of home diaries kept by patients who rated them-
selves as “on without dyskinesias or on without troublesome 
dyskinesias”, “on with troublesome dyskinesias”, “off’, or 
“asleep”. Secondary measures of efﬁ  cacy included changes 
from baseline in UPDRS ADL subscale during “off” periods, 
UPDRS motor subscale during “on” periods, PDQUALIF, 
and investigators’ clinical global impression (CGI-I) of 
patient improvement during the study. Of the enrolled sub-
jects, 87.7% completed 26 weeks of treatment, and 76.1% 
completed the study without deviation from the protocol. 
Compliance was high as measured by pill counts (95% of 
the subjects took at least 90% of scheduled doses).
Mean adjusted total daily “off  ” time decreased from 
baseline by 1.85 hours (29%) in subjects treated with 
rasagiline 1 mg/day, 1.41 hours (23%) in those treated 
with rasagiline 0.5 mg/day, and 0.91 hour (15%) in those 
assigned to placebo. Subjects taking rasagiline 1 mg/day 
had 0.94 hour less “off” time per day (95% CI, 0.51–1.36 
hours, p   0.001) compared with placebo, and those taking 
rasagiline 0.5 mg/day had 0.49 hour less “off” time (95% CI, 
0.08–0.91 hour, p = 0.02) compared with placebo. Second-
ary efﬁ  cacy measures showed improved scores in patients 
receiving both doses of rasagiline, except for PDQUALIF 
score which improved in patients taking 0.5 mg/day rasagi-
line, but not in those taking 1 mg/day rasagiline. The subjects 
assigned to 0.5 mg/day rasagiline experienced increased 
“on” time without troublesome dyskinesias, whereas in 
the 1 mg/day rasagiline group, 32% of increased “on” time 
included troublesome dyskinesias.Neuropsychiatric Disease and Treatment 2008:4(1) 28
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Lasting effect in adjunct therapy with rasagiline 
given once daily (LARGO) (Rascol et al 2005)
The LARGO study was an 18-week, randomized, placebo-
controlled, double-blind, double-dummy, parallel-group 
trial undertaken at 74 centers in Europe, Israel, and Argen-
tina, employing 687 patients. The study compared effects 
of rasagiline with placebo, and effects of entacapone with 
placebo, but it is important to note that it was not designed 
to directly compare rasagiline with entacapone. Subjects 
were required to be on stable levodopa doses for at least 
2 weeks before the baseline visit, and to have motor 
ﬂ  uctuations with at least 1 hour daily in the “off” state. 
Concomitant medications for PD were allowed, except for 
selegiline (held  90 days before study initiation), tolcapone 
(withdrawn  42 days before study), and subjects could 
not have previously used entacapone. No dietary tyramine 
restriction was required.
Subjects were randomly assigned to either 1 mg/day 
rasagiline, 200 mg entacapone with every levodopa dose, 
or placebo. Levodopa dosage could be reduced in the initial 
6 weeks but no change could be made subsequently. The 
groups were well-matched and those on rasagiline had a 
mean age of 63.9 years, mean disease duration of 8.7 years, 
and mean off time of 5.58 hours. Of the 687 subjects who 
initially entered the study, 658 were considered for primary 
analysis based on intention-to-treat analysis. There was a 
statistically signiﬁ  cant reduction in mean daily “off” time 
(primary endpoint) in the rasagiline arm by 1.18 hours, 
and in the entacapone arm by 1.2 hours, as compared 
with placebo (p = 0.0001 and p   0.0001 respectively). 
This translated to an increase in mean “on” time without 
troublesome dyskinesias of 0.85 hour (p = 0.0005) for 
both rasagiline and entacapone. There was no signiﬁ  cant 
difference in mean “on” time with troublesome dyskinesias 
between the two active arms. Rasagiline and entacapone led 
to a small decrease in mean levodopa dose compared to an 
increase in the dose with placebo (rasagiline: −24 mg/daily, 
p = 0.0003; entacapone: −19 mg/day, p = 0.0024). Effects 
of treatment with rasagiline were not affected by simulta-
neous use of dopamine agonists: “off” time was reduced 
by 0.73 hours in the rasagiline group without dopamine 
agonists, versus 0.81 hours in those also taking dopamine 
agonists (p = 0.852). The secondary end-points that were 
signiﬁ  cantly improved by both rasagiline and entacapone, 
were CGI-I score, UPDRS-motor (on state), UPDRS-ADL 
(“off ” state), and UPDRS exploratory subscores measuring 
dopa-responsive symptoms (tremor, rigidity, bradykinesia). 
In the post hoc analysis, other UPDRS subscores, including 
UPDRS postural instability and gait disturbance, and 
UPDRS freezing, were also signiﬁ  cantly improved in the 
rasagiline group, but not in the entacapone group. Finally 
in a pre-planned substudy, mean UPDRS motor scores 
in a practically deﬁ  ned “off” state were improved in the 
rasagiline but not entacapone group.
Safety and tolerability
In early PD trials, analysis of the TEMPO trial revealed 
similar adverse effect proﬁ  les in the placebo and rasagiline 
arms, most commonly infection, headache, dizziness and 
asthenia (Parkinson Study Group 2002). There was a small 
(4.04 mmHg) but signiﬁ  cant (p   0.04) increase in systolic 
blood pressure in the 2 mg dose group compared with 
placebo, but not in the 1 mg dose group. Twenty serious 
adverse reactions (including hospitalizations or new malig-
nancies) occurred in this study; 4 in the placebo group, 6 
in the 1 mg/day, and 10 in the 2 mg/day of rasagiline. Two 
subjects in the 2 mg dose group developed melanoma and 
squamous cell cancer of skin. In the PRESTO trial of rasagi-
line in advanced PD, 87% of the subjects receiving placebo, 
91% of those on 0.5 mg/day rasagiline, and 95% of those 
on 1 mg/day rasagiline reported adverse effects (Parkinson 
Study Group 2005). Anorexia and vomiting were more com-
mon in the rasagiline group, and were dose related: vomiting 
was reported in 2/159 (1.3%) in the placebo group, 6/164 
(3.7%) in the 0.5 mg group (p = 0.31), and 10/149 (6.7%) of 
the 1 mg group (p = 0.03). Balance difﬁ  culty was also more 
common in subjects assigned to rasagiline, and was not dose 
related in this study: imbalance was reported in 1/159 (0.6%) 
in the placebo group, 9/164 (5.5%) in the 0.5 mg group 
(p = 0.03), and 15/149 (3.4%) of the 1 mg group (p = 0.19). 
The incidence of depression was signiﬁ  cantly lower in 
patients on 0.5 mg/day rasagiline compared with placebo 
(p = 0.04). Rasagiline did not have any adverse effects on 
blood pressure and heart rate. In this study, dermatological 
examinations were performed due to the increased frequency 
of skin cancers in PD in general (Fiala et al 2003) and the 
occurrence of melanoma in the TEMPO study. Three patients 
on rasagiline developed melanoma during the study, in 
addition to one identiﬁ  ed prior to initiation of treatment. In 
the LARGO study, adverse events were reported by 50% 
of the 687 patients (Rascol et al 2005). Dopaminergic side 
effects occurred in similar frequency in all the 3 groups. 
Postural hypotension was reported in 2% of the patients in 
the rasagiline as well as entacapone groups, but was absent 
in the placebo group. Fewer patients discontinued rasagiline 
prematurely (10%) compared with entacapone (13%) and Neuropsychiatric Disease and Treatment 2008:4(1) 29
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placebo (15%). Of these subjects, fewer discontinued due to 
adverse events in the rasagiline arm (7/23), compared with 
the entacapone arm (16/30), and the placebo arm (11/35).
Potential medication interactions
The combination of non-selective MAOIs (such as the anti-
depressant medications tranylcypramine and phenelzine) 
and speciﬁ  c serotonin reuptake inhibitors (SSRIs) carries a 
risk of causing the serotonergic syndrome (Sternbach 1991). 
This life-threatening syndrome, thought to be caused by 
overactive brain stem and spinal cord 5-hydroxytryptamine 
receptors, is characterized by acute changes in mental state, 
restlessness, myoclonus, hyperreﬂ  exia, diaphoresis, shiver-
ing and tremors. A 14-day wash out period for MAOIs is 
currently recommended before initiating SSRIs, and close 
follow up is necessary as the serotonergic syndrome has been 
reported even after a 2 week washout period. Conversely, 
if an SSRI is discontinued, a 5-week washout period is 
recommended prior to initiating MAOI therapy. Although 
occurring with non-selective MAOIs, these adverse events 
have raised considerable concern for those taking selective 
MAO-B inhibitors, such as rasagiline and selegiline. Many 
patients with PD suffer from concurrent mood disorders, 
including depression and anxiety (Lauterbach 2004), and 
therefore use of SSRIs and other antidepressants in this 
population is common. The possibility of interactions arising 
as a result of use of selective MAOIs in conjunction with 
SSRIs, tricyclic, or other antidepressant medications in PD 
has been raised by several investigators (Suchowersky and 
deVries 1990; Blackwell 1991; Ritter and Alexander 1997), 
although careful retrospective studies of selegiline use have 
failed to ﬁ  nd such an interaction (Waters 1994; Toyama 
and Iacono 1994; Richard et al 1997). The TEMPO trial 
allowed limited use of amitriptyline, paroxetine, sertraline, 
and trazodone, and both amitriptyline and trazodone were 
allowed in the LARGO study at low and stable doses. 
Maximum daily doses of antidepressants allowed in these 
pivotal phase III trials were: amitriptyline  50 mg, citalo-
pram  20 mg, paroxetine  30 mg, sertaline  100 mg, and 
trazodone  100 mg. In theory, use of such selective MAO-B 
inhibitors at recommended doses should preclude the risk of 
serotonergic syndrome developing, and in practice, many PD 
patients take both a selective MAO-B inhibitor and SSRIs 
concomitantly. In all, 115 subjects were exposed to tricyclics 
and 141 subjects to SSRIs. Unfortunately, given isolated 
case reports documenting such events, caution is mandated, 
and in clinical practice any potential interactions need to be 
thoroughly addressed.
Similarly, use of dextromethorphan or sympathomimetics 
is not recommended as interactions have been reported with 
MAOIs. This includes products containing amphetamines, 
as well as pseudoephedrine, phenylephrine, phenylpropa-
nolamine, and ephedrine. Acceptable alternatives for cold 
and allergy symptoms include diphenhydramine, lorati-
dine, desloratadine, cetirizine, and fexofenadine, as well as 
antihistamine and corticosteroid nasal sprays, and cough 
remedies such as guaifenesin or benzonatate. Meperidine 
is contraindicated and rasagiline should be discontinued at 
least 14 days before projected meperidine administration. 
Other medications contraindicated are analgesics tramadol, 
methadone, and propoxyphene, as well as the tricyclic 
muscle relaxant cyclobenzaprine, and St John’s Wort and 
mirtazapine.
The “cheese effect”
The “cheese effect” is a tyramine-induced pressor response 
in patients taking non-selective MAOIs, such as phenel-
zine or tranylcypromine, resulting from ingesting foods 
containing tyramine (found at signiﬁ  cant levels in aged 
cheeses, cured meats, and other foods), due to inhibition 
of tyramine metabolism by MAO-A in the gastrointestinal 
tract (Youdim 1995). This can result in hypertensive crisis 
secondary to potentiation of pressor effects of indirectly 
acting sympathomimetics when consuming tyramine rich 
foods. Selective MAO-B inhibitors are less likely to cause 
such an effect, as approximately 90% MAO in the intestine 
is the MAO-A isoform. However, the concern remains that 
at higher doses, selectivity may be lost. Moreover the US 
Food and Drug Administration has maintained a warning 
to restrict dietary tyramine. The phase III trials discussed 
in the previous sections (TEMPO, PRESTO, LARGO) did 
not require dietary tyramine restriction. Rasagiline was well-
tolerated in each of these trials. A recent study addressed 
this question by administering a tyramine challenge of 
50–75 mg in 72 subjects with PD taking rasagiline, and 38 
subjects receiving placebo at the end of the TEMPO and 
PRESTO trials. Of the 38 TEMPO subjects receiving 1 mg 
or 2 mg of rasagiline daily, none developed any change in 
pulse rate or systolic blood pressure (SBP) that would sug-
gest a “cheese reaction”. Of the 22 PRESTO subjects taking 
0.5 mg daily rasagiline, 3 subjects developed self-limiting 
SBP increases of  30 mm on 3 consecutive measurements, 
compared with 0/12 taking 1 mg rasagiline daily and 1/21 
taking placebo (deMarcaida et al 2006). Further studies 
are now underway to better deﬁ  ne safety of rasagiline in 
combination with tyramine.Neuropsychiatric Disease and Treatment 2008:4(1) 30
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Effect of rasagiline on cognitive 
and behavioral symptoms in PD
PD treatment has largely involved strategies to correct the 
underlying dopamine deficit. However, management of 
patients with long standing disease is often complicated by 
development of cognitive and behavioral symptoms, result-
ing from medication side effects and/or development of 
extranigral disease, which may involve other neurotransmitter 
systems than dopamine (Tanner 2000; Shults 2003; Lang 
2007). Neuropsychiatric symptoms that have been associ-
ated with PD therapy include hallucinations, depression, 
confusion, impulse control disorders, sleep disorders, daytime 
somnolence, and sleep attacks. Adverse events reported with 
administration of selegiline include confusion, hallucinations, 
and insomnia (the last may be related to its amphetamine 
metabolites) (Montastruc et al 2000; Kamakura et al 2004).
The effects of rasagiline on cognition and behavior were 
examined in a post hoc analysis of the TEMPO and PRESTO 
trials. Incidence of cognitive and behavioral adverse events 
occurring during the 26 weeks of the two trials was reviewed 
for the 1 mg/day rasagiline and placebo groups (Elmer 
et al 2006), and was low in both, despite concurrent use of 
stable doses of dopaminergic agents in PRESTO. In those 
assigned to rasagiline monotherapy 1 mg daily, 1/134 (0.7%) 
experienced hallucinations, compared with 1/138 (0.7%) 
assigned to placebo. No confusion was reported in either 
group. With rasagiline 1 mg daily as adjunctive therapy to 
levodopa, 6/149 (4%) compared with 5/159 (3.1%) taking 
placebo plus levodopa reported hallucinations. Interestingly, 
in the PRESTO study, depression was signiﬁ  cantly lower 
in patients on 0.5 mg/day rasagiline compared with placebo 
(p = 0.04) (Parkinson Study Group 2005). The UPDRS part 
I (Mentation, Behavior, and Mood) subscores were used as 
measures of cognitive change. No signiﬁ  cant differences 
were detected between rasagiline and placebo groups, sug-
gesting a lack of any negative impact by rasagiline on cogni-
tive function. However, caution is warranted in interpreting 
such results using this 4-question rating scale, particularly 
in such a highly selected group of patients. Since the elderly 
with PD are at higher risk for confusion and hallucinations 
associated with PD medication, a post-hoc analysis of the 
TEMPO and PRESTO trials has also investigated any poten-
tial treatment-age interaction for adverse events during the 
trial period including confusion and hallucinations (Goetz 
et al 2006). These investigators divided subjects into older 
(70 years and greater) and younger (less than 70 years) 
groups. In TEMPO, 0/69 older and 1/197 (1%) younger in 
the rasagiline group experienced confusion, compared with 
0/39 older and 0/99 younger subjects in the placebo arm. 
Two of the 69 older (3%) and 1/197 (1%) younger in the 
rasagiline group experienced hallucinations, compared with 
1/39 older (3%) and 0/99 younger subjects in the placebo 
arm (p = 0.66). This investigation therefore failed to detect 
a treatment-age interaction for rasagiline as monotherapy 
in terms of cognitive adverse events: however, it is difﬁ  cult 
to interpret how this translates into normal clinical practice 
given the limitations of such a post-hoc study design.
Potential neuroprotective 
properties
Neuroprotective therapy is aimed at modifying the etio-
pathogenesis and therefore slowing down the progression 
of a neurodegenerative disorder. Various trials have been 
designed to test potential neuroprotectants in PD. However, 
most have been limited by symptomatic effects of drug 
therapy that confound outcomes, in combination with lack 
of validated surrogate disease markers (LeWitt 2006; Biglan 
and Ravina 2007; Hung and Schwarzschild 2007). Signal-
mediated apoptosis is involved in dopamine neuron loss in 
Parkinson’s disease (Hirsch et al 1999), leading to the pos-
sibility of utilizing anti-apoptotic agents as neuroprotective 
therapies. Several in vitro and in vivo animal studies have 
demonstrated the capacity of propargylamines to block 
apoptosis (Blandini et al 2004; Yi et al 2006; Olanow 2006), 
and it has been suggested that based on an anti-apoptotic 
effect, unrelated to MAO-B inhibition, rasagiline is a can-
didate for providing neuroprotection (Mandel et al 2005; 
Youdim et al 2005; Weinreb et al 2005). Rasagiline may 
affect the apoptotic cascade at multiple different points. It 
stabilizes the mitochondrial membrane potential, reducing 
levels of cytochrome c and caspase 3, and preventing DNA 
fragmentation and chromatin clumping (Youdim and Wein-
stock 2001). It prevents the nuclear translocation of GAPDH 
(Maruyama et al 2001). It also results in up-regulation of 
anti-apoptotic proteins including Bcl-2, Bcl-xL (Akao et al 
2002; Maruyama et al 2002; Yi et al 2006), as well as pro-
survival proteins such as glial-derived neurotrophic factor 
(Maruyama et al 2004; Naoi et al 2006). Rasagiline also 
leads to down-regulation of pro-apoptotic molecules like Bax 
and c-Jun (Mandel et al 2005). Although the mechanisms by 
which it acts are not completely understood, it is likely that 
alterations in signaling pathways, for example involving 
protein kinase C (which prevents apoptosis via Bcl-2 and 
MAPK/ERK) are pivotal (Mandel et al 2005).
Rasagiline has neuroprotective activity in vitro in 
SH-SY5Y cells and PC-12 cells and in in vivo models of Neuropsychiatric Disease and Treatment 2008:4(1) 31
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neurodegenerative disease. In vitro, rasagiline has been 
shown to protect against a number of toxins such as 6-
hydroxydopamine (6-OHDA), MPTP, beta-amyloid, and 
serum and nerve growth factor deprivation. It increases sur-
vival of cultured fetal mesencephalic dopaminergic neurons 
(Goggi et al 2000), and has a neuroprotective effect in dopa-
minergic neuroblastoma SH-SY5Y cells (Yi et al 2006) and 
PC12 cells in culture (Mandel et al 2005) in which apoptotic 
cell death was induced by N-methyl-(R)salsolinol. In a rodent 
model of PD, rasagiline has been shown to protect dopamine 
neurons from the toxic effects of unilateral injection of 6-
OHDA. Pre-treatment with rasagiline prevents the loss of 
tyrosine hydroxylase positive dopaminergic neurons in the 
SNc as well as the loss of dopamine terminals in the striatum 
by approximately 35% (Blandini et al 2004; Olanow 2006). 
Again, effects are likely mediated by changes in signaling 
pathways. Proteomic and transcriptomic analysis has identiﬁ  ed 
that rasagiline exerts neurorescue and neurotrophic activity in 
MPTP-treated mice midbrain dopamine neurons, when given 
chronically, by activating tyrosine kinase receptor signaling 
pathway (Rabey et al 2000).It has yet to be determined if long 
term treatment with rasagiline does the same in PD patients.
The delayed start design incorporated into the TEMPO 
trial (2004) suggested a possible disease-modifying effect of 
rasagiline. Currently, a large trial is underway to assess the 
effect of rasagiline on disease progression in early PD (see 
above: A Multi Center, Double Blind, Randomized Start, 
Placebo-Controlled, Parallel-Group Study to Assess Rasa-
giline as a Disease Modifying Therapy in Early Parkinson’s 
Disease Subjects (ADAGIO, see www.clinicaltrials.gov, 
NCT00256204).
Conclusion
Rasagiline prevents dopamine metabolism irreversibly, thus 
increasing levels of dopamine, the result being a symptomatic 
beneﬁ  t in patients with PD. It has demonstrated clinical efﬁ  cacy 
in both early monotherapy and in advanced PD as an adjunct 
to levodopa. Head-to-head trials comparing rasagiline with 
selegiline, or with other dopaminergic agents like DA agonists 
and COMT inhibitors, are needed to test whether symptomatic 
improvement with rasagiline in early PD is superior or not. 
Given its potential role in neuroprotection, rasagiline could 
be of dual beneﬁ  t as monotherapy in early-untreated PD by 
providing symptomatic relief and disease modifying effect. 
However, satisfactory evidence is lacking thus far and this is 
an area of intensive current research. As adjunctive therapy, 
rasagiline has proved efﬁ  cacious and well-tolerated in reducing 
“off”-time, and therefore provides an additional option, with 
a simpler dosing schedule, to dopamine agonists and COMT 
inhibitors for those with motor ﬂ  uctuations.
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